"
Team:Washington/Project/Safety/Secretion
From 2010.igem.org
(Difference between revisions)
| Line 26: | Line 26: | ||
<!---------------------------------------PAGE CONTENT GOES BELOW THIS----------------------------------------> | <!---------------------------------------PAGE CONTENT GOES BELOW THIS----------------------------------------> | ||
Our work on Gram-negative Therapeutics was done only on non-pathogenic strains. We used the Type VI Secretion System from ''Pseudomonas aeruginosa'' PAO1. All modifications and testing of plasmids and fosmids were in non-pathogenic E. Coli strains, namely EPI300, SW102, and BL21. And Team Tse2's strain...MPI?? | Our work on Gram-negative Therapeutics was done only on non-pathogenic strains. We used the Type VI Secretion System from ''Pseudomonas aeruginosa'' PAO1. All modifications and testing of plasmids and fosmids were in non-pathogenic E. Coli strains, namely EPI300, SW102, and BL21. And Team Tse2's strain...MPI?? | ||
| + | |||
| + | The toxin we work with, Tse2, is targeted only to prokaryotic cells so does not pose any danger. | ||
<!---------------------------------------PAGE CONTENT GOES ABOVE THIS----------------------------------------> | <!---------------------------------------PAGE CONTENT GOES ABOVE THIS----------------------------------------> | ||
Revision as of 00:54, 9 September 2010
Our work on Gram-negative Therapeutics was done only on non-pathogenic strains. We used the Type VI Secretion System from Pseudomonas aeruginosa PAO1. All modifications and testing of plasmids and fosmids were in non-pathogenic E. Coli strains, namely EPI300, SW102, and BL21. And Team Tse2's strain...MPI??
The toxin we work with, Tse2, is targeted only to prokaryotic cells so does not pose any danger.
